Clinical Trial Update: Leniolisib for Immune Dysregulation in PIDs [Phase 2]

View source ↗

Summary

Phase 2 trial of leniolisib for immune dysregulation in primary immunodeficiency disorders; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disorders

Drugs mentioned

• Leniolisib (leniolisib)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Primary Immunodeficiency Disorders (PIDs) | Phase 2 | Status: ACTIVE_NOT_RECRUITING